Table 3. Relationship between CENPU expression and prognosis in breast cancer patients from PrognoScan database.
| Dataset | Endpoint | Probe ID | Number | Cox p-value | HR [95% CI] |
| GSE12276 | Relapse Free Survival | 218883_s_at | 204 | 0.04116360 | 1.26 [1.01–1.57] |
| GSE6532-GPL570 | Distant Metastasis Free Survival | 229304_s_at | 87 | 0.00262684 | 2.34 [1.34–4.07] |
| GSE6532-GPL570 | Relapse Free Survival | 229305_at | 87 | 0.01880120 | 1.59 [1.08–2.34] |
| GSE6532-GPL570 | Distant Metastasis Free Survival | 229305_at | 87 | 0.01880120 | 1.59 [1.08–2.34] |
| GSE6532-GPL570 | Relapse Free Survival | 229304_s_at | 87 | 0.00262684 | 2.34 [1.34–4.07] |
| GSE12093 | Distant Metastasis Free Survival | 218883_s_at | 136 | 0.01926210 | 2.30 [1.15–4.62] |
| GSE11121 | Distant Metastasis Free Survival | 218883_s_at | 200 | 0.00213651 | 2.25 [1.34–3.78] |
| GSE2034 | Distant Metastasis Free Survival | 218883_s_at | 286 | 0.00041530 | 1.86 [1.32–2.62] |
| GSE1456-GPL96 | Overall Survival | 218883_s_at | 159 | 0.00015424 | 2.55 [1.57–4.15] |
| GSE1456-GPL96 | Relapse Free Survival | 218883_s_at | 159 | 0.00006250 | 2.71 [1.66–4.42] |
| GSE1456-GPL96 | Disease Specific Survival | 218883_s_at | 159 | 0.00034302 | 2.84 [1.60–5.02] |
| GSE1456-GPL97 | Overall Survival | 229305_at | 159 | 0.00217077 | 2.64 [1.42–4.90] |
| GSE1456-GPL97 | Relapse Free Survival | 229305_at | 159 | 0.01827860 | 2.11 [1.13–3.92] |
| GSE1456-GPL97 | Disease Specific Survival | 229305_at | 159 | 0.02115490 | 2.36 [1.14–4.90] |
| GSE7378 | Disease Free Survival | 218883_s_at | 54 | 0.02591300 | 2.40 [1.11–5.18] |
| GSE3494-GPL96 | Disease Specific Survival | 218883_s_at | 236 | 0.00078752 | 2.25 [1.40–3.62] |
| GSE3494-GPL97 | Disease Specific Survival | 229305_at | 236 | 0.01304810 | 2.37 [1.20–4.69] |
| GSE3494-GPL97 | Disease Specific Survival | 229304_s_at | 236 | 0.00399709 | 4.41 [1.61–12.10] |
| GSE4922-GPL96 | Disease Free Survival | 218883_s_at | 249 | 0.00051062 | 1.98 [1.35–2.90] |
| GSE4922-GPL97 | Disease Free Survival | 229305_at | 249 | 0.00044163 | 2.67 [1.54–4.63] |
| GSE4922-GPL97 | Disease Free Survival | 229304_s_at | 249 | 0.00811801 | 2.91 [1.32–6.42] |
| GSE2990 | Relapse Free Survival | 218883_s_at | 125 | 0.00791330 | 1.49 [1.11–2.01] |
| GSE2990 | Distant Metastasis Free Survival | 218883_s_at | 54 | 0.02650860 | 1.91 [1.08–3.38] |
| GSE2990 | Relapse Free Survival | 218883_s_at | 62 | 0.01579130 | 1.74 [1.11–2.73] |
| GSE7390 | Relapse Free Survival | 218883_s_at | 198 | 0.02837110 | 1.30 [1.03–1.65] |
| GSE7390 | Distant Metastasis Free Survival | 218883_s_at | 198 | 0.00208122 | 1.58 [1.18–2.11] |
| GSE7390 | Overall Survival | 218883_s_at | 198 | 0.00025020 | 1.80 [1.31–2.46] |